Primärtherapie des Ovarialkarzinoms

Zusammenfassung

Das Ovarialkarzinom ist der gynäkologische Tumor mit der höchsten Mortalität. In letzter Zeit hat es zahlreiche neue Erkenntnisse über Stellenwert und Umfang der Primärtherapie dieser Erkrankung gegeben. Die Umsetzung dieser in nationalen und internationalen Standards und Leitlinien implementierten neuen Entwicklungen in den klinischen Alltag ist zur Verbesserung der Situation der Betroffenen dringend erforderlich.

Abstract

Epithelial ovarian cancer is the gynecological tumor with the highest mortality rate. Recently, numerous new findings have emerged about status and extent of surgical therapy of this disease. Innovations regarding chemotherapy are also numerous. It is essential for the improvement of the patients' situation to transfer these new developments already implemented into national and international standards and guidelines to clinical practice.

Schlüsselwörter

Ovarialkarzinom - Operation - Chemotherapie

Key words

Ovarian cancer - chemotherapy - surgery

Literatur

• 1 Trimbos J B. Staging of early ovarian cancer and the impact of lymph node sampling.  Int J Gynecol Cancer. 2000;  10 (Suppl 1) 8-11
• 2 Sakurai S, Shimizu Y, Utsugi K, Umezawa S, Kato T, Fukasawa I, Inaba N, Hasumi K. Validity of complete paraaortic and pelvic lymphadenectomy in apparent stage I (pT1) ovarian carcinoma.  Proc ASCO. 2002;  801
• 3 Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart A M, Torri V, Williams C, Lissoni A, Bonazzi C. International Collaborative Ovarian Neoplasm (ICON) collaborators . International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.  J Natl Cancer Inst. 2003;  95 125-132
• 4 Trimbos J B, Vergote I, Bolis G, Vermorken J B, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S.. EORTC-ACTION collaborators . European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm et al.: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.  J Natl Cancer Inst. 2003;  95 13-25
• 5 Bristow R E, Tomacruz R S, Armstrong D K, Trimble E L, Montz F J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.  J Clin Oncol. 2002;  20 1248-1259
• 6 du Bois A, Pfisterer J, Kellermann L. Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland.  Gynäkologe. 2001;  34 1029-1040
• 7 Rose P G, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin S C, Moore D H. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study.  Proc ASCO. 2002;  802
• 8 The International Collaborative Ovarian Neoplasm (ICON) Group . Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON 3 randomised trial.  Lancet. 2002;  360 505-515
• 9 McGuire W P, Hoskins W J, Brady M F, Kucera P R, Partridge E E, Look K Y, Clarke-Pearson D L, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and Stage IV ovarian cancer.  New Engl J Med. 1996;  334 1-6
• 10 Piccart M J, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R J, Swenerton K D, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy J A, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen J E, Zee B, Paul J, Baron B, Pecorelli S. Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced ovarian cancer.  J Natl Cancer Inst. 2000;  92 699-708
• 11 Muggia F M, Braly P S, Brady M F, Sutton G, Niemann T H, Lentz S L, Alvarez R D, Kucera P R, Small J M. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group Study.  J Clin Oncol. 2000;  18 106-115
• 12 Sandercock J, Parmar M KB, Torri V, Quian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence.  Br J Cancer. 2002;  87 815-824
• 13 Gruppo Interregionale Cooperativo Oncologico Ginecologia (GICOG) . Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer.  Gynecol Oncol. 1992;  45 115-117
• 14 Bolis G, Favalli G, Danese S, Zanaboni F, Mangili G, Scarabelli C, Tateo S, Valsecchi M G, Scarfone G, Richiardi G, Frigerio L, Melpignano M, Villa A, Parazzini F. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.  J Clin Oncol. 1997;  15 1938-1944
• 15 Marth C, Trope C, Vergote I B, Kristensen G B. Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer.  Eur J Cancer. 1998;  34 1175-1180
• 16 du Bois A, Lück H J, Meier W, Adams H P, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J. A randomized clinical trial of Cisplatin/Paclitaxel versus Carboplatin/Paclitaxel as first-line treatment of ovarian cancer.  J Natl Cancer Inst. 2003;  95 1320-1329
• 17 Ozols R F, Bundy B N, Greer B E, Fowler J M, Clarke-Pearson D, Burger R A, Mannel R S, DeGeest K, Hartenbach E M, Baergen R. Phase III Trial of Carboplatin and Paclitaxel compared with Cisplatin and Paclitaxel in patients with optimally resected stage III Ovarian cancer. A Gynecologic Oncology Group Study.  J Clin Oncol. 2003;  21 3194-3200